Genetic Signatures (ASX:GSS) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GSS Panoramica delle azioni

Genetic Signatures Limited opera come società di diagnostica molecolare (MDx) in Australia, Asia Pacifico, Americhe, Europa, Medio Oriente, Israele e Africa.

Informazioni sull'azienda

GSS analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 43.18% all'anno

Analisi del rischio

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Genetic Signatures Limited Concorrenti

Proteomics International Laboratories

ASX:PIQ

AU$114.0m

Trajan Group Holdings

ASX:TRJ

AU$170.5m

OncoSil Medical

ASX:OSL

AU$41.6m

EZZ Life Science Holdings

ASX:EZZ

AU$86.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Genetic Signatures
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.74
Massimo di 52 settimane	AU$0.85
Minimo di 52 settimane	AU$0.38
Beta	0.055
1Variazione di 1 mese	-3.90%
Variazione a 3 mesi	1.37%
Variazione di 1 anno	59.14%
3Variazione a 3 anni	-50.17%
Variazione a 5 anni	-28.33%
Variazione dall'IPO	52.58%

Notizie e aggiornamenti recenti

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Rendimenti per gli azionisti

	GSS	AU Life Sciences	AU Mercato
7D	5.7%	-2.8%	1.1%
1Y	59.1%	5.0%	11.4%

Ritorno vs Industria: GSS ha superato il Australian Life Sciences che ha restituito -0.2 % nell'ultimo anno.

Rendimento vs Mercato: GSS ha superato il mercato Australian che ha restituito 11.2 % nell'ultimo anno.

Volatilità dei prezzi

Is GSS's price volatile compared to industry and market?
GSS volatility
GSS Average Weekly Movement	4.9%
Life Sciences Industry Average Movement	9.4%
Market Average Movement	8.3%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.5%

Prezzo delle azioni stabile: GSS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 5% ) di GSS è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2001	n/a	Neil Gunn	www.geneticsignatures.com

Genetic Signatures Limited opera come società di diagnostica molecolare (MDx) in Australia, Asia Pacifico, Americhe, Europa, Medio Oriente, Israele e Africa. Progetta e produce una suite di prodotti basati sulla reazione a catena della polimerasi in tempo reale per il rilevamento di malattie infettive con il marchio EasyScreen. L'azienda fornisce anche la tecnologia della piattaforma MDx 3Base, che consente ai laboratori ospedalieri e di patologia di effettuare lo screening di una serie di agenti patogeni infettivi.

Genetic Signatures Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Genetic Signatures con la sua capitalizzazione di mercato?
GSS statistiche fondamentali
Capitalizzazione di mercato	AU$168.80m
Guadagni(TTM)	-AU$18.04m
Ricavi(TTM)	AU$15.99m

10.5x

Rapporto P/S

-9.3x

Rapporto P/E

GSS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
GSS Conto economico (TTM)
Ricavi	AU$15.99m
Costo del fatturato	AU$9.79m
Profitto lordo	AU$6.20m
Altre spese	AU$24.24m
Guadagni	-AU$18.04m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.08
Margine lordo	38.79%
Margine di profitto netto	-112.83%
Rapporto debito/patrimonio netto	0%

Come si è comportato GSS nel lungo periodo?

Vedi performance storica e confronto

GSS Panoramica delle azioni

Premi

Analisi del rischio

Genetic Signatures Limited Concorrenti

ASX:PIQ

AU$114.0m

ASX:TRJ

AU$170.5m

ASX:OSL

AU$41.6m

ASX:EZZ

AU$86.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

Recent updates

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Genetic Signatures Limited Riepilogo dei fondamenti

10.5x